LifeStance Health Group, Inc. LFST

Healthcare SIC 8000 - Services-Health Services NAICS Health Care and Social Assistance derived Nasdaq

Unless stated otherwise or the context otherwise requires, the terms "we," "us," "our," "our business," "LifeStance" and "our Company" and similar references refer to LifeStance Health Group, Inc. and its consolidated subsidiaries and supported practices. References to "our employees" and "our clinicians" refer collectively to employees and clinicians, respectively, of our subsidiaries and supported practices. References to "our patients" refer to the patients treated by such clinicians.

Our vision is a truly healthy society where mental and physical healthcare are unified to make lives better. Our mission is to help people lead healthier, more fulfilling lives by improving access to trusted, affordable and personalized mental healthcare. To fulfill this mission, we have built one of the nation's largest outpatient mental health platforms based on number of clinicians and geographic scale.

Last close 12.93 2026-10-23
Market cap $4.94B 2026-06-30 share count
52-week range 4.77 - 13.56

Valuation FY2025 figures against the last close

P/S3.5x
P/E—
P/FCF44.9x
EV/EBITDA75.6x
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue $1.42B$1.25B$1.06B$859.5M$667.5M—$212.5M—
SG&A $382.2M$363.1M$410.8M$378.0M$433.7M—$41.1M—
Total operating expenses $1.40B$1.28B$1.24B$1.07B$953.9M—$197.3M—
Operating income $24.1M-$31.6M-$189.1M-$210.2M-$286.4M—$15.2M—
Interest expense $11.7M$26.5M$21.2M$19.9M$38.9M—$5.4M—
Pre-tax income $12.4M-$57.6M-$206.6M-$232.7M-$333.1M—$7.9M—
Income tax $2.7M$170.0K$20.3M$17.2M$25.9M—$2.2M—
Net income $9.7M-$57.4M-$186.3M-$215.6M-$307.2M—$5.7M—
Shares, diluted (wtd. avg.) 391.1M379.1M367.5M355.3M327,523———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents $248.6M$154.6M$78.8M$108.6M$148.0M$18.8M$3.5M$11.3M
Receivables $95.7M$131.8M$125.4M$100.9M$76.1M$43.7M——
Total current assets $416.2M$312.5M$225.7M$233.2M$266.5M$76.3M——
Property, plant and equipment $161.6M$166.0M$188.2M$194.2M$152.2M$59.3M——
Goodwill $1.29B$1.29B$1.29B$1.27B$1.20B$1.10B$926.7M—
Other intangibles $177.7M$190.8M$221.1M$263.3M$300.4M$332.8M——
Total assets $2.20B$2.12B$2.11B$2.17B$1.93B$1.57B——
Accounts payable $6.1M$7.2M$7.1M$12.3M$14.2M$7.7M——
Short-term debt $14.5M$7.2M$2.9M$2.3M$1.3M$3.7M——
Total current liabilities $252.0M$228.9M$202.9M$176.0M$116.8M$75.9M——
Long-term debt $265.9M$279.8M$280.3M$225.1M$157.4M$362.5M——
Total liabilities $682.9M$672.0M$681.0M$655.1M$382.1M$536.9M——
Retained earnings -$808.6M-$818.3M-$760.8M-$572.6M-$357.1M-$13.1M——
Total equity $1.52B$1.45B$1.43B$1.52B$1.55B$997.8M-$166.4M-$109.1M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating cash flow $146.2M$107.3M-$16.9M$52.8M$9.4M—$17.0M—
Depreciation and amortisation $41.6M$40.7M$37.4M$28.9M$15.1M—$3.0M—
Stock-based compensation $74.7M$76.2M$99.4M$187.4M$259.4M—$54.0K—
Capital expenditure $36.1M$21.6M$40.5M$79.3M$94.5M—$14.3M—
Investing cash flow -$36.1M-$21.6M-$60.3M-$139.5M-$194.1M—-$73.4M—
Financing cash flow -$16.0M-$9.9M$47.4M$47.3M$313.9M—$48.5M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-170798.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -500M 0 500M 1B 1.5B Revenue, FY2019: 212.5M Net income, FY2019: 5.7M Revenue, FY2021: 667.5M Net income, FY2021: -307.2M Revenue, FY2022: 859.5M Net income, FY2022: -215.6M Revenue, FY2023: 1.1B Net income, FY2023: -186.3M Revenue, FY2024: 1.3B Net income, FY2024: -57.4M Revenue, FY2025: 1.4B Net income, FY2025: 9.7M FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $212.5M — $667.5M $859.5M $1.06B $1.25B $1.42B
Gross profit — — — — — — — —
Net income — $5.7M — -$307.2M -$215.6M -$186.3M -$57.4M $9.7M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Other event Item 8.01
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Officer or director change Item 5.02
  • Other event Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 8000

TickerCompanyMarket capP/ERevenue growth
PRVA Privia Health Group, Inc. $2.86B 124.5x 22.3%
WGS GeneDx Holdings Corp. $1.67B — 40.0%
PNTG Pennant Group, Inc. $1.46B 49.9x 36.3%
USPH U S PHYSICAL THERAPY INC /NV $1.32B 62.3x 16.3%
INNV InnovAge Holding Corp. $1.30B — 11.8%
OMDA Omada Health, Inc. $1.16B — 53.2%
SRTA Strata Critical Medical, Inc. $412.3M 9.3x 34.3%
DCGO DocGo Inc. $26.8M — -47.7%